caprotec bioanalytics Completes Series B Financing Round of EUR 4 Million
caprotec bioanalytics GmbH announced the closing of a EUR 4 million ($5.1M) Series B Financing Round with existing investors Creathor Venture, IBB Beteiligungsgesellschaft, ERP Startfonds, and well-known private investors. The proceeds will enable further development and marketing of the Company’s proprietary CCMS (Capture Compound Mass Spectrometry) platform technology for analyzing complex protein mixtures.
“CCMS is a broadly applicable technology to investigate small molecule protein interactions. It enables the isolation and identification of native functionally selected proteins directly from a complex biological sample,” stated Prof. Köster, founder and CEO of caprotec bioanalytics GmbH.
Karlheinz Schmelig, Managing Director at Creathor Venture commented, “The completion of this investment round in a challenging financing environment demonstrates that caprotec, with its exceptional management and ground breaking new technology, stands out among other companies in this industry.”
The proceeds from this financing round will be used to further develop caproKitsTM as tools for the worldwide R&D community to identify functionally selected protein classes and the company’s ImproMedTM (”improved medicines”) application to profile drug-protein interactions, generating the information to structurally optimize the drug molecule for increasing efficacy and reducing adverse side effects.
Other news from the department business & finance
